A Comparison of Diagnostics Kits Used in Russia for Identification of Antigens of Noroviruses
- Authors: Sakalkina E.V.1, Parkina N.V.1, Olneva T.A.1, Tagirova Z.G.2, Podkolzin A.T.1, Shipulin G.A.1
-
Affiliations:
- Central Research Institute of Epidemiology
- Dagestan State Medical University
- Issue: Vol 33, No 1 (2018)
- Pages: 44-48
- Section: Experimental Works
- URL: https://journal-vniispk.ru/0891-4168/article/view/178251
- DOI: https://doi.org/10.3103/S0891416818010111
- ID: 178251
Cite item
Abstract
Three diagnostic kits for detection of antigens of noroviruses were evaluated and compared. These were (1) the RIDAQUICK® Norovirus test kit (R-Biopharm AG, Germany), (2) the RIDASCREEN® Norovirus test kit (R-Biopharm AG, Germany), and (3) the Norovirus-antigen IFA-BEST kit (VECTOR-BEST, Russia). The study was carried out with a panel containing 90 norovirus-positive (GI/GII) stool samples (GI.2, GI.3, GI.4, GI.6, GII.1, GII.2, GII.3 and GII.4 (including GII.4_New_Orlean and GII.4_Sydney), and GII.5, GII.6, GII.7, GII.10, GII.15. and GII.17) and 30 negative samples. The AmpliSens OKI scrin kit (FSR no. 2008/02265 dated November 17, 2011) was used as for comparison for identification of noroviruses of the GII genogroup. A technique that included confirmative sequencing of the capsid and polymerase gene fragments was used to determine noroviruses of the GI genogroup. Only 26 of 90 (28.9%) reference-positive samples were determined as norovirus-positive ones with any of the three diagnostic kits used in the present study. False-positive results of the test were revealed only with the Norovirus-antigen IFA-BEST kit in 8 out of 30 (26.7%) reference-negative samples. The estimated indices of diagnostic sensitivity and specificity of the RIDAQUICK® Norovirus test kit were 12.2 and 100%, respectively. They were 26.7 and 100% for the RIDASCREEN® Norovirus test kit and 17.8 and 73.3% for the Norovirus-antigen IFA-BEST kit.
About the authors
E. V. Sakalkina
Central Research Institute of Epidemiology
Author for correspondence.
Email: evzayceva@cmd.su
Russian Federation, Moscow, 111123
N. V. Parkina
Central Research Institute of Epidemiology
Email: evzayceva@cmd.su
Russian Federation, Moscow, 111123
T. A. Olneva
Central Research Institute of Epidemiology
Email: evzayceva@cmd.su
Russian Federation, Moscow, 111123
Z. G. Tagirova
Dagestan State Medical University
Email: evzayceva@cmd.su
Russian Federation, Mahachkala, 367000
A. T. Podkolzin
Central Research Institute of Epidemiology
Email: evzayceva@cmd.su
Russian Federation, Moscow, 111123
G. A. Shipulin
Central Research Institute of Epidemiology
Email: evzayceva@cmd.su
Russian Federation, Moscow, 111123
Supplementary files
